Fig. 3

ACE2 predicts the therapeutic options in BC. A Correlations between ACE2 and clinic-pathological features in BC. Significance was calculated with Pearson’s Chi-squared test or Student’s t-test. ns-P > 0.05, ***P < 0.001, ****P < 0.0001. B Correlations between ACE2 and the enrichment scores of several therapeutic signatures. C Correlation between ACE2 and the drug-target genes extracted from the Drugbank database. D Differences in IC50 of common anti-cancer drugs between the high and low ACE2 groups. Significance was calculated with Student’s t-test. ****P < 0.0001